Table 3.

Comparison of survival times (mo.) between patient treatment groups.

Variable	TACE median survival (95% CI)	Y90 median survival (95% CI)	p value between treatment groups
Overall groups	8.5(8–10)	11.5(8–16)	<0.05
Gender
Males	8(7–10)	10(7–13)	ns
Females	12(10–15)	19(16–32)	<0.05
P value for gender	p<0.001	ns
Cirrhosis
No Cirrhosis	12(10–35)	22(16–40)	ns
Cirrhosis	8(8–9)	10(7–14)	<0.05
P value for cirrhosis	p<0.0001	p<0.05
Tumor Size
<5 cm.	10(9–12)	8(5–18)	ns
≥5 cm.	8(6–10)	17(7–40)	<0.05
P value for tumor size	ns	ns
Tumor Number
<5	10(8–13)	14(7–19)	ns
≥5	8(6–10)	9(5–13)	ns
P value for tumor number	ns	p<0.05
Portal Vein Thrombosis
Absent	12(10–14)	16(12–20)	<0.05
Present	7(5–9)	5(4–9)	ns
P value for presence PVT	p<0.0001	p<0.0001
Alpha-fetoprotein
<25 ng/ml	15(14–18)	18(13–28)	ns
≥25 ng/ml	7(6–8)	8(6–13)	ns
P value for elevated AFP	p<0.0001	p<0.05
Bilrubin
<1.5 mg/dL	12(10–13)	13(9–18)	ns
≥1.5 mg/dL	5(3–5)	4(2–10)	ns
P value for elevated Bilirubin	p<0.0001	p<0.0001
Albumin
≥3.5 g/dL	13(10–15)	22(13–32)	<0.05
<3.5 g/dL	7(6–9)	8(6–13)	ns
P value for low albumin	p<0.0001	p<0.001